CoChat
Sign Up
Cited by 26Cardiac Valve Diseases and TreatmentsAortic Disease and Treatment ApproachesHeart Failure Treatment and Management

Biomarkers Associated with Mortality in Aortic Stenosis: A Systematic Review and Meta-Analysis

Open access
White, Madeline, Baral, Ranu, Ryding, Alisdair, Tsampasian, Vasiliki, Ravindrarajah, Thuwarahan, Garg, Pankaj, Koskinas, Konstantinos C., Clark, Allan +1 more·2021·Medical Sciences
DOI 10.3390/medsci9020029PMC PMC8163007
Open this paper in CoChat — free accountOpen PDF

Abstract

The optimal timing of aortic valve replacement (AVR) remains controversial. Several biomarkers reflect the underlying pathophysiological processes in aortic stenosis (AS) and may be of use as mortality predictors. The aim of this systematic review and meta-analysis is to evaluate the blood biomarkers utilised in AS and assess whether they associate with mortality. PubMed and Embase were searched for studies reporting baseline biomarker level and mortality outcomes in patients with AS. A total of 83 studies met the inclusion criteria and were systematically reviewed. Of these, 21 reporting brain natriuretic peptide (BNP), N-terminal pro B-type natriuretic peptide (NT-proBNP), Troponin and Galectin-3 were meta-analysed. Pooled analysis demonstrated that all-cause mortality was significantly associated with elevated baseline levels of BNP (HR 2.59; 95% CI 1.95–3.44; p < 0.00001), NT-proBNP (HR 1.73; 95% CI 1.45–2.06; p = 0.00001), Troponin (HR 1.65; 95% CI 1.31–2.07; p < 0.0001) and Galectin-3 (HR 1.82; 95% CI 1.27–2.61; p < 0.001) compared to lower baseline biomarker levels. Elevated levels of baseline BNP, NT-proBNP, Troponin and Galectin-3 were associated with increased all-cause mortality in a population of patients with AS. Therefore, a change in biomarker level could be considered to refine optimal timing of intervention. The results of this meta-analysis highlight the importance of biomarkers in risk stratification of AS, regardless of symptom status.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/medsci9020029

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Elevated levels of brain natriuretic peptide, cardiac troponin, and galectin-3 are correlated with all-cause mortality in individuals with CAVS.

    “Previous studies showed that elevated levels of brain natriuretic peptide, cardiac troponin, and galectin-3 are correlated with all-cause mortality in individuals with CAVS.6,7,8,9,10”

    From Aortic valve-specific genes dysregulated in calcific aortic valve stenosis as potential biomarkers and therapeutic targets (2025) · cites this paper as [10]

    The Discussion reports that elevated baseline BNP, troponin, and galectin-3 are associated with increased all-cause mortality in patients with aortic stenosis. However, the Eligibility Criteria include patients with aortic stenosis generally, and the paper does not establish this association specifically for the calcific subtype (CAVS). (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 79

  1. [1]Zakkar M. Bryan A.J. Angelini G.D. Aortic stenosis: Diagnosis and management BMJ 2016 355 10.1136/bmj.i5425 27760734 · DOI
  2. [2]Maganti K. Rigolin V.H. Sarano M.E. Bonow R.O. Valvular heart disease: Diagnosis and management Mayo Clin. Proc. 2010 85 483 500 10.4065/mcp.2009.0706 20435842 PMC2861980 · DOI
  3. [3]Dweck M.R. Boon N.A. Newby D.E. Calcific Aortic Stenosis J. Am. Coll. Cardiol. 2012 60 1854 1863 10.1016/j.jacc.2012.02.093 23062541 · DOI · Paper page
  4. [5]Lindman B.R. Dweck M.R. Lancellotti P. Généreux P. Piérard L.A. O’Gara P.T. Bonow R.O. Management of Asymptomatic Severe Aortic Stenosis: Evolving Concepts in Timing of Valve Replacement JACC Cardiovasc. Imaging 2020 13 481 493 10.1016/j.jcmg.2019.01.036 31202751 · DOI
  5. [6]Bergler-Klein J. Klaar U. Heger M. Rosenhek R. Mundigler G. Gabriel H. Binder T. Pacher R. Maurer G. Baumgartner H. Natriuretic Peptides Predict Symptom-Free Survival and Postoperative Outcome in Severe Aortic Stenosis Circulation 2004 109 2302 2308 10.1161/01.CIR.0000126825.50903.18 15117847 · DOI · Paper page
  6. [8]Dahou A. Clavel M.A. Capoulade R. O’Connor K. Ribeiro H.B. Côté N. le Ven F. Rodés-Cabau J. Dumesnil J.G. Mathieu P. B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin for Risk Stratification in Low-Flow, Low-Gradient Aortic Stenosis: A Substudy of the TOPAS Study JACC Cardiovasc. Imaging 2018 11 939 947 10.1016/j.jcmg.2017.06.018 28917673 · DOI · Paper page
  7. [9]Giordana F. D’Ascenzo F. Nijhoff F. Moretti C. D’Amico M. Zoccai G.B. Sinning J.M. Nickenig G. van Mieghem N.M. Chieffo A. Meta-analysis of predictors of all-cause mortality after transcatheter aortic valve implantation Am. J. Cardiol. 2014 114 1447 1455 10.1016/j.amjcard.2014.07.081 25217456 · DOI
  8. [11]Shamseer L. Moher D. Clarke M. Ghersi D. Liberati A. Petticrew M. Shekelle P. Stewart L.A. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation BMJ 2015 349 g7647 10.1136/bmj.g7647 25555855 · DOI · Paper page
  9. [13]The Cochrane Collaboration Review Manager 5.3 (RevMan 5.3) Version 5.3 The Nordic Cochrane Centre, The Cochrane Collaboration, Cochrane Collab Copenhagen, Denmark 2014
  10. [14]Higgins J.P.T. Thompson S.G. Quantifying heterogeneity in a meta-analysis Stat. Med. 2002 21 1539 1558 10.1002/sim.1186 12111919 · DOI · Paper page
  11. [15]Redfors B. Furer A. Lindman B.R. Burkhoff D. Marquis-Gravel G. Francese D.P. Ben-Yehuda O. Pibarot P. Gillam L.D. Leon M.B. Biomarkers in Aortic Stenosis: A Systematic Review Struct. Heart 2017 1 18 30 10.1080/24748706.2017.1329959 · DOI
  12. [16]Kim J.B. Kobayashi Y. Moneghetti K.J. Brenner D.A. O’Malley R. Schnittger I. Wu J.C. Murtagh G. Beshiri A. Fischbein M. GDF-15 (Growth Differentiation Factor 15) Is Associated With Lack of Ventricular Recovery and Mortality After Transcatheter Aortic Valve Replacement Circ. Cardiovasc. Interv. 2017 10 10.1161/CIRCINTERVENTIONS.117.005594 29222133 PMC6470358 · DOI
  13. [17]Koskinas K.C. O’Sullivan C.J. Heg D. Praz F. Stortecky S. Pilgrim T. Buellesfeld L. Jüni P. Windecker S. Wenaweser P. Effect of B-type Natriuretic Peptides on Long-Term Outcomes after Transcatheter Aortic Valve Implantation Am. J. Cardiol. 2015 116 1560 1565 10.1016/j.amjcard.2015.08.016 26428025 · DOI
  14. [18]Lim P. Monin J. Monchi M. Garot J. Pasquet A. Hittinger L. Vanoverschelde J. Carayon A. Gueret P. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: Role of B-type natriuretic peptide Eur. Heart J. 2004 25 2048 2053 10.1016/j.ehj.2004.09.033 15541842 · DOI
  15. [19]Nakatsuma K. Taniguchi T. Morimoto T. Shiomi H. Ando K. Kanamori N. Murata K. Kitai T. Kawase Y. Izumi C. B-type natriuretic peptide in patients with asymptomatic severe aortic stenosis Heart 2019 105 384 390 10.1136/heartjnl-2018-313746 30530820 · DOI
  16. [20]Matthew G. Nessmith M.D. Hidekatsu Fukuta M.D. Steffen Brucks M.D. William C. Little M.D. Usefulness of an elevated B-type natriuretic peptide in predicting survival in patients with aortic stenosis treated without surgery Am. J. Cardiol. 2005 96 1445 1448 10.1016/j.amjcard.2005.06.092 16275196 · DOI
  17. [21]O’Sullivan C.J. Stortecky S. Heg D. Jüni P. Windecker S. Wenaweser P. Impact of B-type natriuretic peptide on short-term clinical outcomes following transcatheter aortic valve implantation EuroIntervention 2015 10 e1 e8 10.4244/EIJV10I10A200 24429160 · DOI
  18. [22]Parenica J. Nemec P. Tomandl J. Ondrasek J. Pavkova-Goldbergova M. Tretina M. Jarkovsky J. Littnerova S. Poloczek M. Pokorny P. Prognostic utility of biomarkers in predicting of one-year outcomes in patients with aortic stenosis treated with transcatheter or surgical aortic valve implantation PLoS ONE 2012 7 e48851 10.1371/journal.pone.0048851 23272045 PMC3522688 · DOI
  19. [23]Pedrazzini G.B. Masson S. Latini R. Klersy C. Rossi M.G. Pasotti E. Faletra F.F. Siclari F. Minervini F. Moccetti T. Comparison of Brain Natriuretic Peptide Plasma Levels Versus Logistic EuroSCORE in Predicting In-Hospital and Late Postoperative Mortality in Patients Undergoing Aortic Valve Replacement for Symptomatic Aortic Stenosis Am. J. Cardiol. 2008 102 749 754 10.1016/j.amjcard.2008.04.055 18774001 · DOI
  20. [24]Ramchand J. Patel S.K. Kearney L.G. Matalanis G. Farouque O. Srivastava P.M. Burrell L.M. Plasma ACE2 Activity Predicts Mortality in Aortic Stenosis and Is Associated with Severe Myocardial Fibrosis JACC Cardiovasc. Imaging. 2019 13 655 664 10.1016/j.jcmg.2019.09.005 31607667 · DOI
  21. [25]Sato K. Kumar A. Krishnaswamy A. Mick S. Desai M.Y. Griffin B.P. Kapadia S.R. Popović Z.B. B-type natriuretic peptide is associated with remodeling and exercise capacity after transcatheter aortic valve replacement for aortic stenosis Clin. Cardiol. 2019 42 270 276 10.1002/clc.23138 30565264 PMC6712326 · DOI
  22. [26]Wernly B. Lichtenauer M. Jirak P. Eder S. Reiter C. Kammler J. Kypta A. Jung C. Franz M. Hoppe U.C. Soluble ST2 predicts 1-year outcome in patients undergoing transcatheter aortic valve implantation Eur. J. Clin. Investig. 2017 47 149 157 10.1111/eci.12719 28036122 · DOI
  23. [27]Abramowitz Y. Chakravarty T. Jilaihawi H. Lee C. Cox J. Sharma R.P. Mangat G. Cheng W. Makkar R.R. Impact of Preprocedural B-Type Natriuretic Peptide Levels on the Outcomes after Transcatheter Aortic Valve Implantation Am. J. Cardiol. 2015 116 1904 1909 10.1016/j.amjcard.2015.09.031 26602075 · DOI
  24. [28]Andrinopoulou E.-R. Rizopoulos D. Geleijnse M.L. Lesaffre E. Bogers A.J.J.C. Takkenberg J.J.M. Dynamic prediction of outcome for patients with severe aortic stenosis: Application of joint models for longitudinal and time-to-event data BMC Cardiovasc. Disord. 2015 1528 1 8 10.1186/s12872-015-0035-z PMC4425918 25943388 · DOI
  25. [29]Ben-Dor I. Minha S. Barbash I.M. Aly O. Dvir D. Deksissa T. Okubagzi P. Torguson R. Lindsay J. Satler L.F. Correlation of brain natriuretic peptide levels in patients with severe aortic stenosis undergoing operative valve replacement or percutaneous transcatheter intervention with clinical, echocardiographic, and hemodynamic factors and prognosis Am. J. Cardiol. 2013 112 574 579 10.1016/j.amjcard.2013.04.023 23683951 · DOI
  26. [30]Bergler-Klein J. Mundigler G. Pibarot P. Burwash I.G. Dumesnil J.G. Blais C. Fuchs C. Mohty D. Beanlands R.S. Hachicha Z. B-type natriuretic peptide in low-flow, low-gradient aortic stenosis: Relationship to hemodynamics and clinical outcome: Results from the Multicenter Truly or Pseudo-Severe Aortic Stenosis (TOPAS) study Circulation 2007 115 2848 2855 10.1161/CIRCULATIONAHA.106.654210 17515464 · DOI
  27. [31]Goodman A. Kusunose K. Popovic Z.B. Parikh R. Barr T. Sabik J.F. Rodriguez L.L. Svensson L.G. Griffin B.P. Desai M.Y. Synergistic Utility of Brain Natriuretic Peptide and Left Ventricular Strain in Patients With Significant Aortic Stenosis J. Am. Heart Assoc. 2016 5 e002561 10.1161/JAHA.115.002561 26732551 PMC4859373 · DOI
  28. [32]Gotzmann M. Czauderna A. Aweimer A. Hehnen T. Bosche L. Lind A. Kloppe A. B-type Natriuretic Peptide Is a Strong Independent Predictor of Long-Term Outcome After Transcatheter Aortic Valve Implantation J Heart Valve Dis. 2014 23 537 544 10.13140/2.1.4834.1287 25799701 · DOI
  29. [33]Joelle Kefer M.D. Christophe Beauloye M.D. Parla Astarci M.D. Jean Renkin M.D. David Glineur M.D. Alain DekleermaekeraJean-Louis Vanoverschelde M.D. Usefulness of B-type natriuretic peptide to predict outcome of patients treated by transcatheter aortic valve implantation Am. J. Cardiol. 2010 106 1782 1786 10.1016/j.amjcard.2010.07.051 21055712 · DOI
  30. [34]Antonini-Canterin F. Popescu B.A. Popescu A.C. Beladan C.C. Korcova R. Piazza R. Cappelletti P. Rubin D. Cassin M. Faggiano P. Heart failure in patients with aortic stenosis: Clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement Int. J. Cardiol. 2008 128 406 412 10.1016/j.ijcard.2007.05.039 17662495 · DOI
  31. [35]Capoulade R. Magne J. Dulgheru R. Hachicha Z. Dumesnil J.G. O’Connor K. Arsenault M. Bergeron S. Pierard L.A. Lancellotti P. Prognostic value of plasma B-type natriuretic peptide levels after exercise in patients with severe asymptomatic aortic stenosis Heart 2014 100 1606 1612 10.1136/heartjnl-2014-305729 24993604 · DOI
  32. [36]Henri C. Dulgheru R. Magne J. Caballero L. Laaraibi S. Davin L. Kou S. Voilliot D. Nchimi A. Oury C. Impact of Serial B-Type Natriuretic Peptide Changes for Predicting Outcome in Asymptomatic Patients with Aortic Stenosis Can. J. Cardiol. 2016 32 183 189 10.1016/j.cjca.2015.06.007 26371385 · DOI
  33. [37]Iwahashi N. Nakatani S. Umemura S. Kimura K. Kitakaze M. Usefulness of plasma B-type natriuretic peptide in the assessment of disease severity and prediction of outcome after aortic valve replacement in patients with severe aortic stenosis J. Am. Soc. Echocardiogr. 2011 24 984 991 10.1016/j.echo.2011.03.012 21570253 · DOI
  34. [39]Kaneko H. Hoelschermann F. Tambor G. Okamoto M. Neuss M. Butter C. Impact of N-terminal pro-B-type natriuretic peptide response on long-term prognosis after transcatheter aortic valve implantation for severe aortic stenosis and heart failure Heart Vessels. 2018 34 777 783 10.1007/s00380-018-1297-z 30443765 · DOI
  35. [40]Köhler W.M. Freitag-Wolf S. Lambers M. Lutz M. Niemann P.M. Petzina R. Lutter G. Bramlage P. Frey N. Frank D. Preprocedural but not periprocedural high-sensitive Troponin T levels predict outcome in patients undergoing transcatheter aortic valve implantation Cardiovasc. Ther. 2016 34 385 396 10.1111/1755-5922.12208 27380819 · DOI
  36. [41]Krau N.-C. Lünstedt N.-S. Freitag-Wolf S. Brehm D. Petzina R. Lutter G. Bramlage P. Dempfle A. Frey N. Frank D. Elevated growth differentiation factor 15 levels predict outcome in patients undergoing transcatheter aortic valve implantation Eur. J. Heart Fail. 2015 17 945 955 10.1002/ejhf.318 26230285 · DOI
  37. [42]Lindman B.R. Clavel M.A. Abu-Alhayja’a R. Côté N. Dagenais F. Novak E. Voisine P. Poulin A. Arsenault B.J. Desmeules P. Multimarker Approach to Identify Patients with Higher Mortality and Rehospitalization Rate After Surgical Aortic Valve Replacement for Aortic Stenosis JACC Cardiovasc. Interv. 2018 11 2172 2181 10.1016/j.jcin.2018.07.039 30409274 PMC6233732 · DOI
  38. [43]Lindman B.R. Breyley J.G. Schilling J.D. Vatterott A.M. Zajarias A. Maniar H.S. Damiano R.J. Moon M.R. Lawton J.S. Gage B.F. Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement Heart 2015 101 1382 1388 10.1136/heartjnl-2015-307742 26037104 PMC4598053 · DOI · Paper page
  39. [44]López-Otero D. Trillo-Nouche R. Gude F. Cid-Alvarez B. Ocaranza-Sanchez R. Alvarez M.S. Lear P.V. Gonzalez-Juanatey J.R. Pro B-type natriuretic peptide plasma value: A new criterion for the prediction of short- and long-term outcomes after transcatheter aortic valve implantation Int. J. Cardiol. 2013 168 1264 1268 10.1016/j.ijcard.2012.11.116 23280329 · DOI
  40. [45]Raposeiras-Roubín S. Abu-Assi E. López-Rodríguez E. Agra-Bermejo R. Pereira-López E.M. Calvo-Iglesias F. Íñiguez-Romo A. NT-proBNP for risk stratification of nonagenarian patients with severe symptomatic aortic stenosis Int. J. Cardiol. 2016 223 785 786 10.1016/j.ijcard.2016.08.195 27573609 · DOI
  41. [47]Sinning J.M. Wollert K.C. Sedaghat A. Widera C. Radermacher M.C. Descoups C. Hammerstingl C. Weber M. Stundl A. Ghanem A. Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement Am. Heart J. 2015 170 821 829 10.1016/j.ahj.2015.07.003 26386807 · DOI
  42. [48]Solberg O.G. Ueland T. Wergeland R. Dahl C.P. Aakhus S. Aukrust P. Gullestad L. High-sensitive troponin T and N-terminal-brain-natriuretic-peptide predict outcome in symptomatic aortic stenosis Scand. Cardiovasc. J. 2012 46 278 285 10.3109/14017431.2012.687836 22545649 · DOI
  43. [49]Stähli B.E. Gebhard C. Saleh L. Falk V. Landmesser U. Nietlispach F. Maisano F. Lüscher T.F. Maier W. Binder R.K. N-terminal pro-B-type natriuretic peptide-ratio predicts mortality after transcatheter aortic valve replacement Catheter. Cardiovasc. Interv. 2015 85 1240 1247 10.1002/ccd.25788 25511571 · DOI
  44. [50]Stundl A. Lünstedt N.S. Courtz F. Freitag-Wolf S. Frey N. Holdenrieder S. Zur B. Grube E. Nickenig G. Werner N. Soluble ST2 for Risk Stratification and the Prediction of Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation Am. J. Cardiol. 2017 120 986 993 10.1016/j.amjcard.2017.06.033 28739033 · DOI
  45. [51]Vale N.C. Teles R.C. Madeira S. Brito J. Almeida M.S. Nolasco T. Abecasis J. Rodrigues G. Carmo J. Furstenau M. Post-procedural N-terminal pro-brain natriuretic peptide predicts one-year mortality after transcatheter aortic valve implantation Rev. Port. Cardiol. 2018 37 67 73 10.1016/j.repc.2017.06.016 29317115 · DOI
  46. [52]Agoston-Coldea L. Bheecarry K. Cionca C. Petra C. Strimbu L. Ober C. Lupu S. Fodor D. Mocan T. Incremental Predictive Value of Longitudinal Axis Strain and Late Gadolinium Enhancement Using Standard CMR Imaging in Patients with Aortic Stenosis J. Clin. Med. 2019 8 165 10.3390/jcm8020165 PMC6406708 30717180 · DOI
  47. [53]Anantha-Narayanan M. Malik U. Mbai M. Megaly M. Florea V. Sharma A. Cavalcante J.L. Garcia S. Impact of diastolic dysfunction on long-term mortality and quality of life after transcatheter aortic valve replacement Catheter. Cardiovasc. Interv. 2019 95 1034 1041 10.1002/ccd.28444 31419009 · DOI
  48. [54]Auensen A. Hussain A.I. Falk R.S. Walle-Hansen M.M. Bye J. Pettersen K.I. Aukrust P. Ueland T. Gullestad L.L. Associations of brain-natriuretic peptide, high-sensitive troponin T, and high-sensitive C-reactive protein with outcomes in severe aortic stenosis PLoS ONE 2017 12 e0179304 10.1371/journal.pone.0179304 28604834 PMC5467862 · DOI
  49. [55]Baldenhofer G. Laule M. Mockel M. Sanad W. Knebel F. Dreger H. Leonhardt F. Sander M. Grubitzsch H. Baumann G. Mid-regional pro-adrenomedullin (MR-proADM) and mid-regional pro-atrial natriuretic peptide (MR-proANP) in severe aortic valve stenosis: Association with outcome after transcatheter aortic valve implantation (TAVI) Clin. Chem. Lab. Med. 2017 55 275 283 10.1515/cclm-2015-0419 27522619 · DOI
  50. [56]Csordas A. Nietlispach F. Schuetz P. Huber A. Müller B. Maisano F. Taramasso M. Moarof I. Obeid S. Stähli B.E. Midregional Proadrenomedullin Improves Risk Stratification beyond Surgical Risk Scores in Patients Undergoing Transcatheter Aortic Valve Replacement PLoS ONE 2015 10 e0143761 10.1371/journal.pone.0143761 26630012 PMC4667909 · DOI
  51. [57]Elhmidi Y. Bleiziffer S. Piazza N. Ruge H. Krane M. Deutsch M.A. Hettich I. Voss B. Mazzitelli D. Lange R. The Evolution and Prognostic Value of N-terminal Brain Natriuretic Peptide in Predicting 1-year Mortality in Patients Following Transcatheter Aortic Valve Implantation J. Invasive Cardiol. 2013 25 38 44 23293174
  52. [58]Frank D. Stark S. Lutz M. Weissbrodt A. Freitag-Wolf S. Petzina R. Rosenberg M. Lutter G. Frey N. Preprocedural high-sensitive troponin predicts survival after transcatheter aortic valve implantation (TAVI) Int. J. Cardiol. 2013 169 e38 e39 10.1016/j.ijcard.2013.08.108 24063930 · DOI
  53. [59]Agoston-Coldea L. Bheecarry K. Petra C. Strambu L. Ober C. Revnic R. Lupu S. Mocan T. Fodor D. The value of global longitudinal strain and galectin-3 for predicting cardiovascular events in patients with severe aortic stenosis Med. Ultrason. 2018 20 205 10.11152/mu-1456 29730688 · DOI
  54. [60]Chin C.W.L. Shah A.S.V. McAllister D.A. Cowell S.J. Alam S. Langrish J.P. Strachan F.E. Hunter A.L. Choy A.M. Lang C.C. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis Eur. Heart J. 2014 35 2312 2321 10.1093/eurheartj/ehu189 24829362 PMC4156973 · DOI · Paper page
  55. [61]Cho K.I. Cho S.H. Her A.-Y. Singh G.B. Shin E.-S. Prognostic Utility of Neutrophil-to-Lymphocyte Ratio on Adverse Clinical Outcomes in Patients with Severe Calcific Aortic Stenosis PLoS ONE 2016 11 e0161530 10.1371/journal.pone.0161530 27548384 PMC4993489 · DOI
  56. [62]Cimadevilla C. Cueff C. Hekimian G. Dehoux M. Lepage L. Iung B. Duval X. Huart V. Tubach F. Vahanian A. Prognostic value of B-type natriuretic peptide in elderly patients with aortic valve stenosis: The COFRASA-GENERAC study Heart 2013 99 461 467 10.1136/heartjnl-2012-303284 23349346 · DOI
  57. [63]Farré N. Gómez M. Molina L. Cladellas M. Blé M. Roqueta C. Ascoeta M.S. Comin-Colet J. Vila J. Bruguera J. Prognostic Value of NT-proBNP and an Adapted Monin Score in Patients With Asymptomatic Aortic Stenosis Rev. Española Cardiol. 2014 67 52 57 10.1016/j.recesp.2013.06.023 24774264 · DOI
  58. [64]Ferrer-Sistach E. Lupón J. Cediel G. Teis A. Gual F. Serrano S. Vallejo N. Juncà G. López-Ayerbe J. Bayés-Genís A. High-sensitivity troponin T in asymptomatic severe aortic stenosis Biomarkers 2019 24 334 340 10.1080/1354750X.2019.1567818 30632403 · DOI
  59. [65]Nguyen V. Cimadevilla C. Arangalage D. Dehoux M. Codogno I. Duval X. Tubiana S. Vahanian A. Messika-Zeitoun D. Determinants and prognostic value of B-type natriuretic peptide in patients with aortic valve stenosis Int. J. Cardiol. 2017 230 371 377 10.1016/j.ijcard.2016.12.100 28062138 · DOI
  60. [66]Rheude T. Pellegrini C. Núñez J. Joner M. Trenkwalder T. Mayr N.P. Holdenrieder S. Bodi V. Koenig W. Kasel A.M. Differential Prognostic Value of Galectin-3 According to Carbohydrate Antigen 125 Levels in Transcatheter Aortic Valve Implantation Rev. Española Cardiol. 2019 72 907 915 10.1016/j.recesp.2018.08.022 30482731 · DOI
  61. [67]Rheude T. Pellegrini C. Schmid H. Trenkwalder T. Mayr N.P. Joner M. Kasel A.M. Holdenrieder S. Nunez J. Sanchis J. Comparison of Carbohydrate Antigen 125 and N-Terminal Pro-Brain Natriuretic Peptide for Risk Prediction After Transcatheter Aortic Valve Implantation Am. J. Cardiol. 2018 121 461 468 10.1016/j.amjcard.2017.11.020 29306485 · DOI
  62. [68]Weber M. Hausen M. Arnold R. Nef H. Moellman H. Berkowitsch A. Elsaesser A. Brandt R. Mitrovic V. Hamm C. Prognostic value of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis Heart 2006 92 1639 1644 10.1136/hrt.2005.085506 16740919 PMC1861212 · DOI
  63. [69]Akodad M. Spaziano M. Chevalier B. Garot P. Benamer H. Dinan-Zannier A. Troussier X. Unterseeh T. Champagne S. Hovasse T. Prognostic Impact of Pre-Transcatheter and Post-Transcatheter Aortic Valve Intervention Troponin: A Large Cohort Study J. Am. Heart Assoc. 2019 8 e011111 10.1161/JAHA.118.011111 30866687 PMC6475053 · DOI
  64. [70]Chorianopoulos E. Krumsdorf U. Geis N. Pleger S.T. Giannitsis E. Katus H.A. Bekeredjian R. Preserved prognostic value of preinterventional troponin T levels despite successful TAVI in patients with severe aortic stenosis Clin. Res. Cardiol. 2014 103 65 72 10.1007/s00392-013-0624-8 24096554 · DOI
  65. [71]Kofler M. Reinstadler S.J. Stastny L. Dumfarth J. Reindl M. Wachter K. Rustenbach C.J. Müller S. Feuchtner G. Mende M. Prognostic Implications of Pre-Procedural High-Sensitivity Cardiac Troponin T in Patients Undergoing Transcatheter Aortic Valve Replacement JACC Cardiovasc. Interv. 2017 10 2345 2346 10.1016/j.jcin.2017.09.020 29169507 · DOI
  66. [72]Koifman E. Garcia-Garcia H.M. Alraies M.C. Buchanan K. Hideo-Kajita A. Steinvil A. Rogers T. Ben-Dor I. Pichard A.D. Torguson R. Correlates and Significance of Elevation of Cardiac Biomarkers Elevation Following Transcatheter Aortic Valve Implantation Am. J. Cardiol. 2017 120 850 856 10.1016/j.amjcard.2017.05.059 28688702 · DOI
  67. [73]Sinning J.M. Hammerstingl C. Schueler R. Neugebauer A. Keul S. Ghanem A. Mellert F. Schiller W. Müller C. Vasa-Nicotera M. The prognostic value of acute and chronic troponin elevation after transcatheter aortic valve implantation EuroIntervention 2016 11 1522 1529 10.4244/EIJY15M02_02 25671517 · DOI
  68. [74]Saito T. Hojo Y. Hirose M. Ikemoto T. Katsuki T. Kario K. High-sensitivity troponin T is a prognostic marker for patients with aortic stenosis after valve replacement surgery J. Cardiol. 2013 61 342 347 10.1016/j.jjcc.2013.01.005 23473763 · DOI
  69. [75]Baldenhofer G. Zhang K. Spethmann S. Laule M. Eilers B. Leonhardt F. Sanad W. Dreger H. Sander M. Grubitzsch H. Galectin-3 predicts short- and long-term outcome in patients undergoing transcatheter aortic valve implantation (TAVI) Int. J. Cardiol. 2014 177 912 917 10.1016/j.ijcard.2014.10.010 25456698 · DOI
  70. [76]Bobrowska B. Wieczorek-Surdacka E. Kruszelnicka O. Chyrchel B. Surdacki A. Dudek D. Clinical correlates and prognostic value of plasma galectin-3 levels in degenerative aortic stenosis: A single-center prospective study of patients referred for invasive treatment Int. J. Mol. Sci. 2017 18 947 10.3390/ijms18050947 PMC5454860 28468272 · DOI
  71. [77]Elmariah S. Mccarthy C. Ibrahim N. Furman D. Mukai R. Magaret C. Rhyne R. Barnes G. van Kimmenade R.R.J. Januzzi J.L. Multiple biomarker panel to screen for severe aortic stenosis: Results from the CASABLANCA study Open Heart 2018 5 916 10.1136/openhrt-2018-000916 PMC6242008 30487984 · DOI
  72. [78]Spampinato R.A. Bochen R. Sieg F. Weiss S. Kornej J. Haunschild J. von Aspern K. Strotdrees E. Noack T. Lehmann S. Multi-biomarker mortality prediction in patients with aortic stenosis undergoing valve replacement J. Cardiol. 2020 76 154 162 10.1016/j.jjcc.2020.02.019 32273155 · DOI
  73. [79]Frunza O. Russo I. Saxena A. Shinde A.V. Humeres C. Hanif W. Rai V. Su Y. Frangogiannis N.G. Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis Am. J. Pathol. 2016 186 1114 1127 10.1016/j.ajpath.2015.12.017 26948424 PMC4861760 · DOI
  74. [80]Blanda V. Bracale U.M. di Taranto M.D. Fortunato G. Galectin-3 in cardiovascular diseases Int. J. Mol. Sci. 2020 21 9232 10.3390/ijms21239232 PMC7731136 33287402 · DOI
  75. [81]Madamanchi C. Alhosaini H. Sumida A. Runge M.S. Obesity and natriuretic peptides, BNP and NT-proBNP: Mechanisms and diagnostic implications for heart failure Int. J. Cardiol. 2014 176 611 617 10.1016/j.ijcard.2014.08.007 25156856 PMC4201035 · DOI · Paper page
  76. [82]Musa T.A. Treibel T.A. Vassiliou V.S. Captur G. Singh A. Chin C. Dobson L.E. Pica S. Loudon M. Malley T. Myocardial Scar and Mortality in Severe Aortic Stenosis Circulation 2018 138 1935 1947 10.1161/CIRCULATIONAHA.117.032839 30002099 PMC6221382 · DOI
  77. [83]Vassiliou V.S. Perperoglou A. Raphael C.E. Joshi S. Malley T. Everett R. Halliday B. Pennell D.J. Dweck M.R. Prasad S.K. Midwall Fibrosis and 5-Year Outcome in Moderate and Severe Aortic Stenosis J. Am. Coll. Cardiol. 2017 69 1755 1756 10.1016/j.jacc.2017.01.034 28359524 · DOI
  78. [84]O’Leary J.M. Clavel M.-A. Chen S. Goel K. O’Neill B. Elmariah S. Crowley A. Alu M.C. Thourani V.H. Leon M.B. Association of Natriuretic Peptide Levels After Transcatheter Aortic Valve Replacement With Subsequent Clinical Outcomes JAMA Cardiol. 2020 186 1114 1127 10.1001/jamacardio.2020.2614 PMC7364343 32667623 · DOI
  79. [85]Ryding A.D.S. Kumar S. Worthington A.M. Burgess D. Prognostic value of brain natriuretic peptide in noncardiac surgery: A meta-analysis Anesthesiology 2009 111 311 319 10.1097/ALN.0b013e3181aaeb11 19602961 · DOI

Cited by

Sorted by citations

Authors
White, M., Baral, R., Ryding, A., Tsampasian, V., Ravindrarajah, T., Garg, P., Koskinas, K. C., Clark, A., & Vassiliou, V. S.
Affiliations
  • University of East Anglia (GB)
  • University Hospital of Bern (CH)
Corresponding author
Tsampasian, Vasiliki
ORCID
Venue
Medical Sciences
Publisher
MDPI AG
Published
2021-05-17
Volume
9
Issue
2
Pages
29
ISSN
2076-3271 (ISSN-L)
DOI
10.3390/medsci9020029
PMC
PMC8163007
OpenAlex
W3162393819
Cited by
26
References
5
Citations by year
2026: 3 · 2025: 4 · 2024: 4 · 2023: 9 · 2022: 5 · 2021: 1
FWCI
0.93
Type
journal article
Language
en
Open access
Licence
Locations
  • Medical Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UEA Digital Repository (University of East Anglia) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institute for Health and Care Research (ACF-2019-15-003)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Aortic Disease and Treatment Approaches
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
aortic stenosis, blood biomarkers, all-cause mortality, brain natriuretic peptide, NT-proBNP, troponin, galectin-3, risk stratification
MeSH terms
Aortic Valve, Aortic Valve Stenosis, Humans, Troponin, Biomarkers, Natriuretic Peptide, Brain, Galectin 3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review